Kestra Advisory Services’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$84.8K Buy
35,798
+500
+1% +$706 ﹤0.01% 3366
2026
Q2
$59.3K Buy
35,298
+500
+1% +$727 ﹤0.01% 3207
2026
Q1
$45.9K Sell
34,798
-60
-0.2% -$107 ﹤0.01% 3060
2025
Q4
$65.2K Buy
34,858
+652
+2% +$1.25K ﹤0.01% 3769
2025
Q3
$43.8K Buy
+34,206
New +$46.3K ﹤0.01% 2865

Other funds holding PACB

Kestra Advisory Services's PACB Position: Q3 2026 in Review

Kestra Advisory Services increased its Pacific Biosciences (PACB) stake by 1.4% in Q3 2026, buying an estimated $706 and bringing the position to 35,798 shares worth $84.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3366.

Kestra Advisory Services first reported a position in PACB in Q3 2025 and has held it in 5 quarters since. 204 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Kestra Advisory Services held 35,798 shares of Pacific Biosciences worth $84.8K as of Q3 2026.
  • Kestra Advisory Services bought 500 Pacific Biosciences shares in Q3 2026, an estimated $706.
  • Pacific Biosciences made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #3366 holding.
  • Kestra Advisory Services first reported a position in Pacific Biosciences in Q3 2025 and has held it in 5 quarters since.
  • 204 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.